Head to Head Analysis: Roivant Sciences (NASDAQ:ROIV) vs. Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares Pharming Group and Roivant Sciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13 million	1.78	$2.85 million	$0.12	78.67
Roivant Sciences	$8.26 million	2,916.39	-$299.77 million	($0.53)	-62.92

Pharming Group has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pharming Group and Roivant Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Analyst Ratings

This is a breakdown of recent recommendations for Pharming Group and Roivant Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2	0	3	0	2.20
Roivant Sciences	1	2	10	1	2.79

Pharming Group currently has a consensus target price of $38.67, indicating a potential upside of 309.60%. Roivant Sciences has a consensus target price of $45.64, indicating a potential upside of 36.84%. Given Pharming Group’s higher possible upside, equities analysts plainly believe Pharming Group is more favorable than Roivant Sciences.

Volatility and Risk

Pharming Group has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.